Breast cancer is the most frequently diagnosed cancer in women, with estrogen receptor
positive (ER+) breast cancer making up approximately 75% of all breast cancers diagnosed …

Endocrine therapy (ET) is a pivotal strategy to manage early-and advanced-stage estrogen
receptor-positive (ER+) breast cancer. In patients with metastatic breast cancer (MBC) …

Several new systemic therapy options have become available for patients with metastatic
breast cancer, which have led to improvements in survival. In addition to patient and clinical …

Aim Real-life analysis of overall survival (OS) trends among metastatic breast cancer (MBC)
patients may help define medical needs and evaluate the impact of public health …

Tumors that express detectable levels of the product of the ESR1 gene (estrogen receptor-α;
ERα) represent the single largest molecular subtype of breast cancer. More women …

Obesity is a risk factor for estrogen receptor-positive (ER+) breast cancer after menopause.
The pro-proliferative effects of estrogens are well characterized and there is a growing body …

Most prostate cancers are androgen-sensitive malignancies whose growths depend on the
transcriptional activity of the androgen receptor (AR). In the 1940s, Charles Huggins …

Alkenylboranes have been vital reagents in modern synthetic organic chemistry, whose
carbon–boron bond is transformable into a carbon–carbon bond stereoretentively to give …

For more than 25 years, tamoxifen has been the gold standard for the endocrine treatment of
all stages of oestrogen-receptor-positive breast cancer, and the World Health Organization …

Cancer is expected to continue as a major health and economic problem worldwide. Several
factors are contributing to the increasing economic burden imposed by cancer, with the cost …